Of interest, in that trial, the improved pCR rate with atezolizumab was independent of tumor PD-L1 expression—a finding different from the observation in NeoTRIP, and at odds with the results in women with metastatic TNBC, in whom a benefit from atezolizumab with nab-paclitaxel was restricted to PD-L1 + tumors56. The gene discussed is CD274; the disease is neoplasm.